FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298399> ?p ?o ?g. }

• W4286298399 endingPage "2035" @default.
• W4286298399 startingPage "2035" @default.
• W4286298399 abstract "2035 Background: Isocitrate dehydrogenase ( IDH) 1 and IDH2 mutations ( IDH1/2mt) are the most common mutations in gliomas, occurring in over 70% of low grade and 20% of higher grade gliomas. IDH1/2mts are associated with improved prognosis, although tumors typically recur and progress to a higher grade despite first lines of treatment. Recent preclinical studies have suggested IDHmt and accumulation of 2-HG confer a “BRCAness” phenotype, a vulnerability that can be targeted through PARPi. To test this hypothesis, we conducted a multicenter study of olaparib monotherapy in patients (pts) with IDH1/2mt gliomas that had progressed despite standard therapy. Methods: Eligible pts had contrast enhancing and biopsy confirmed IDH1/2mt glioma that progressed despite standard therapy. Pts with prior treatment with PARPi or IDHmt inhibitors were excluded. The primary endpoint was overall response rate (ORR). Secondary objectives were progression free survival (PFS), overall survival (OS) and duration of response (DR). Olaparib 300 mg orally twice daily was given. A standard Simon 2 stage design was used. Stage 1 included 15 pts. If 2/15 pts responded stage 2 would expand by 30 pts. Responses were assessed with RANO criteria and reviewed centrally. Results: 15 evaluable pts were enrolled. Most recent histology as per 2021 WHO classification was 12 astrocytoma (4 grade 2, 3 grade 3, 5 grade 4) and 3 oligodendroglioma (2 grade 2, 1 grade 3). A total of 13 pts’ tumors had IDH1 R132H mutations; 2 pts had IDH2mt (R172G, R172K). All pts had >1 and 10 pts had >2 prior lines of systemic therapy (median 2, range 1-4). Most toxicities were grade 1 or 2. Nausea (67%) and fatigue (47%) were most frequent. Grade 3 lymphopenia, thrombocytopenia, and hypertension were seen in 1 patient each. Best response was stable disease (SD) in 9 pts and 6 pts had disease progression (PD). The median PFS was 3.6 months, 6-month PFS rate 26.7%, median OS 13.2 months. For pts with SD, median PFS was 5.5 months; 4 pts had SD for > 6 months. 2/6 pts with PD had confirmed WHO grade 4 by histology; 4 had CDKN2A deletion. CDKN2A deletion was unknown for 2 pts. Conclusions: Olaparib was well tolerated in this pt population. The study did not meet the pre-specified response-based threshold for moving to step 2, but prolonged SD was observed in pts with grades 2 and 3 histologies, suggesting olaparib monotherapy could be of clinical benefit in select pts. Grade 4 tumors per the 2021 WHO classification defined by histology or CDKN2A mutation derived minimal to no benefit from this drug highlighting the usefulness of this new classification for future patient stratification and trial design and suggesting investigation of this treatment earlier in the disease course might be of interest. Further studies are needed to identify other molecular or clinical predictive markers of benefit from PARPi as well as novel drug combinations for improved efficacy in this population. Clinical trial information: NCT03212274." @default.
• W4286298399 created "2022-07-21" @default.
• W4286298399 creator A5001015275 @default.
• W4286298399 creator A5014264452 @default.
• W4286298399 creator A5018071939 @default.
• W4286298399 creator A5020238544 @default.
• W4286298399 creator A5025489794 @default.
• W4286298399 creator A5026112756 @default.
• W4286298399 creator A5033270808 @default.
• W4286298399 creator A5037364310 @default.
• W4286298399 creator A5037535298 @default.
• W4286298399 creator A5040738951 @default.
• W4286298399 creator A5047308475 @default.
• W4286298399 creator A5049054322 @default.
• W4286298399 creator A5058970015 @default.
• W4286298399 creator A5067747332 @default.
• W4286298399 creator A5080736692 @default.
• W4286298399 creator A5089994023 @default.
• W4286298399 creator A5091053515 @default.
• W4286298399 date "2022-06-01" @default.
• W4286298399 modified "2023-10-02" @default.
• W4286298399 title "Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma." @default.
• W4286298399 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.2035" @default.
• W4286298399 hasPublicationYear "2022" @default.
• W4286298399 type Work @default.
• W4286298399 citedByCount "4" @default.
• W4286298399 countsByYear W42862983992022 @default.
• W4286298399 countsByYear W42862983992023 @default.
• W4286298399 crossrefType "journal-article" @default.
• W4286298399 hasAuthorship W4286298399A5001015275 @default.
• W4286298399 hasAuthorship W4286298399A5014264452 @default.
• W4286298399 hasAuthorship W4286298399A5018071939 @default.
• W4286298399 hasAuthorship W4286298399A5020238544 @default.
• W4286298399 hasAuthorship W4286298399A5025489794 @default.
• W4286298399 hasAuthorship W4286298399A5026112756 @default.
• W4286298399 hasAuthorship W4286298399A5033270808 @default.
• W4286298399 hasAuthorship W4286298399A5037364310 @default.
• W4286298399 hasAuthorship W4286298399A5037535298 @default.
• W4286298399 hasAuthorship W4286298399A5040738951 @default.
• W4286298399 hasAuthorship W4286298399A5047308475 @default.
• W4286298399 hasAuthorship W4286298399A5049054322 @default.
• W4286298399 hasAuthorship W4286298399A5058970015 @default.
• W4286298399 hasAuthorship W4286298399A5067747332 @default.
• W4286298399 hasAuthorship W4286298399A5080736692 @default.
• W4286298399 hasAuthorship W4286298399A5089994023 @default.
• W4286298399 hasAuthorship W4286298399A5091053515 @default.
• W4286298399 hasConcept C104317684 @default.
• W4286298399 hasConcept C126322002 @default.
• W4286298399 hasConcept C127848430 @default.
• W4286298399 hasConcept C143998085 @default.
• W4286298399 hasConcept C181199279 @default.
• W4286298399 hasConcept C182979987 @default.
• W4286298399 hasConcept C207103383 @default.
• W4286298399 hasConcept C2776059313 @default.
• W4286298399 hasConcept C2777150147 @default.
• W4286298399 hasConcept C2777931997 @default.
• W4286298399 hasConcept C2778227246 @default.
• W4286298399 hasConcept C2778880634 @default.
• W4286298399 hasConcept C2779962180 @default.
• W4286298399 hasConcept C44249647 @default.
• W4286298399 hasConcept C501734568 @default.
• W4286298399 hasConcept C502942594 @default.
• W4286298399 hasConcept C55493867 @default.
• W4286298399 hasConcept C71924100 @default.
• W4286298399 hasConcept C82381507 @default.
• W4286298399 hasConcept C86803240 @default.
• W4286298399 hasConceptScore W4286298399C104317684 @default.
• W4286298399 hasConceptScore W4286298399C126322002 @default.
• W4286298399 hasConceptScore W4286298399C127848430 @default.
• W4286298399 hasConceptScore W4286298399C143998085 @default.
• W4286298399 hasConceptScore W4286298399C181199279 @default.
• W4286298399 hasConceptScore W4286298399C182979987 @default.
• W4286298399 hasConceptScore W4286298399C207103383 @default.
• W4286298399 hasConceptScore W4286298399C2776059313 @default.
• W4286298399 hasConceptScore W4286298399C2777150147 @default.
• W4286298399 hasConceptScore W4286298399C2777931997 @default.
• W4286298399 hasConceptScore W4286298399C2778227246 @default.
• W4286298399 hasConceptScore W4286298399C2778880634 @default.
• W4286298399 hasConceptScore W4286298399C2779962180 @default.
• W4286298399 hasConceptScore W4286298399C44249647 @default.
• W4286298399 hasConceptScore W4286298399C501734568 @default.
• W4286298399 hasConceptScore W4286298399C502942594 @default.
• W4286298399 hasConceptScore W4286298399C55493867 @default.
• W4286298399 hasConceptScore W4286298399C71924100 @default.
• W4286298399 hasConceptScore W4286298399C82381507 @default.
• W4286298399 hasConceptScore W4286298399C86803240 @default.
• W4286298399 hasIssue "16_suppl" @default.
• W4286298399 hasLocation W42862983991 @default.
• W4286298399 hasOpenAccess W4286298399 @default.
• W4286298399 hasPrimaryLocation W42862983991 @default.
• W4286298399 hasRelatedWork W1574091519 @default.
• W4286298399 hasRelatedWork W1911924650 @default.
• W4286298399 hasRelatedWork W2016770193 @default.
• W4286298399 hasRelatedWork W2094537892 @default.
• W4286298399 hasRelatedWork W2126817554 @default.
• W4286298399 hasRelatedWork W2157219413 @default.
• W4286298399 hasRelatedWork W2760885207 @default.
• W4286298399 hasRelatedWork W3013369088 @default.

• next